Atopic dermatitis (AD) is a chronic, pruritic, inflammatory dermatosis that affects up to 25% of
children and 2% to 3% of adults. This guideline addresses important clinical questions that …

Importance Most clinical trials assessing systemic immunomodulatory treatments for patients
with atopic dermatitis are placebo-controlled. Objective To compare the effectiveness and …

This guideline was developed as a joint interdisciplinary European project, including
physicians from all relevant disciplines as well as patients. It is a consensus‐based …

Background There are gaps in our knowledge of the prevalence of adult atopic dermatitis
(AD). Objective To estimate the prevalence of AD in adults and by disease severity. Methods …

Background The adult burden of atopic dermatitis (AD) is poorly characterized. Objective We
sought to characterize AD burden in adults with moderate to severe disease from the …

Importance Pruritus, a hallmark of atopic dermatitis (AD), is thought to disrupt sleep, yet little
is known about how variations in disease activity and severity of this common childhood …

The lack of core outcome sets for atopic eczema (AE) is a major obstacle for advancing
evidence-based treatment. The global Harmonising Outcome Measures for Eczema (HOME) …

Background Many patients with moderate-to-severe atopic dermatitis (AD) require systemic
immunomodulating treatment to achieve adequate disease control. Objective We sought to …

Core outcome sets are critically important outcomes that should be measured in clinical
trials. Their absence in atopic dermatitis is a form of research waste and impedes combining …

OBJECTIVE: There are few studies on the natural history of milk allergy. Most are single-site
and not longitudinal, and these have not identified a means for early prediction of outcomes …